Trial Profile
A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms BALANCE 205
- Sponsors Hanmi Pharmaceutical
- 11 Jun 2019 Results of an exploratory subgroup analysis assessing effect of Efpeglenatide on body wieght, BMI and waist circumference from baseline to wk 21 vs placebo presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results of a sub-analysis assessing efficacy of Efpeglenatide presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 17 Oct 2018 Patients were not recruited from Czech Republic.